Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes

Diabetes Care

Volumn 31, Issue 6, 2008, Pages 1165-1169

  Saraheimo, Markku ^a,b   Forsblom, Carol ^a,b   Thorn, Lena ^a,b   Wadén, Johan ^a,b   Rosengård BÄrlund, Milla ^a,b   Heikkilä, Outi ^a,b   Hietala, Kustaa ^a   Gordin, Daniel ^b   Frystyk, Jan ^c   Flyvbjerg, Allan ^a,b   Groop, Per Henrik ^a,b,d  

^a FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALBUMIN; CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ADULT; ALBUMINURIA; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GROUPS BY AGE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION; BLOOD; CHRONIC KIDNEY FAILURE; FINLAND; MIDDLE AGED; PREDICTION AND FORECASTING;

ADIPONECTIN; ADULT; ALBUMINURIA; BODY MASS INDEX; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS;

EID: 47949121132     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc07-2306     Document Type: Article

References (23)

1. Scherer P, Williams S, Fogliano M, Baldini G, Lodish H: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746-26749, 1995
2. Zoccali C, Mallamaci F, Panuccio V, Tripepi G, Cutrupi S, Parlongo S, Catalano F, Tanaka S, Ouchi N: Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int 63 (Suppl. 84):S98-S102, 2003
3. Stenvinkel P, Marchlewska A, Pecoits- Filho R, Heimburger O, Zhang Z, Hoff C, Holmes C, Axelsson J, Arvidsson S, Schalling M, Barany P, Lindholm B, Nordfors L: Adiponectin in renal disease: Relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 65: 274-281, 2004
4. Imagawa A, Funahashi T, Nakamura T, Moriwaki M, Tanaka S, Nishizawa H, Sayama K, Uno S, Iwahashi H, Miyagawa J-I, MatsuzawaY: Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1. Diabetes Care 25:1665-1666, 2002
5. Saraheimo M, Forsblom C, Fagerudd J, Teppo AM, Pettersson-Fernholm K, Frystyk J, Flyvbjerg A, Groop PH, Finn Diane Study Group: Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 28:1410-1414, 2005
6. Schalkwijk CG, Chaturvedi N, Schram MT, Fuller JH, Stehouwer CD, EURO-DIAB Prospective Complications Study Group: Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab 91:129-135, 2006
7. Chudek J, Adamczak M, Karkoszka H, Budzinski G, Ignacy W, Funahashi T, Matsuzawa Y, Cierpka L, Kokot F, Wiecek A: plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 35:2186-2189, 2003
8. Fujita H, Morii T, Koshimura J, Ishikawa M, Kato M, Miura T, Sasaki H, Narita T, Ito S, Kakei M: Possible relationship between adiponectin and renal tubular injury in diabetic nephropathy. Endocr J 53:745-752, 2006
9. Goldstein BJ, Scalai R: Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89:2563-2568, 2004
10. Zoccali C, Mallamaci F, Tripepi G, Benedetto F, Cutrupi S, Parlongo S, Malatino L, Bonanno G, SeminaraG, Rapisarda F, Fatuzzo P, Buemi M, Nococia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134-141, 2002
11. Becker B, Kornenberg F, Kielstein JT, Haller H, Morath C, Ritz E, Fliser D, MMKD Study Group: Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 16:1091-1098, 2005
12. Hadjadj S, Aubert R, Fumeron F, Pean F, Tichet J, Roussel R, Marre M, SURGENE and DESIR Study Groups: Increased plasma adiponectin concentrations associated with microangiopathy in type 1 diabetic subjects. Diabetologia 48:1088-1092, 2005
13. Thorn L, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M, Rönnback M, Rosengård- Barlund M, Björkesten CG, Taskinen MR, Groop PH, FinnDiane Study Group: Metabolic syndrome in type 1 diabetes. Diabetes Care 28:2019-2024, 2005
14. Cockroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
15. Frystyk J, Tarnow L, Krarup Hansen T, Parving HH, Flyvbjerg A: Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 48:1911-1918, 2005
16. Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, Pereira AA, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sar- nak MJ: Adiponectin and mortality in patients with chronic kidney disease. JAm Soc Nephrol 17:2599-606, 2006
17. Furuhashi M, Ura N, Takizawa H, Yo- shida D. Moniwa N, Murakami H, Hi- gashiura K, Shimamoto K: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42:76-81, 2003
18. Fernandez M, Triplitt C, Wajcberg E, Sriwijilkamol AA, Musi N, Cusi K, DeFronzo R, Cersosimo E: Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. Diabetes Care 31:121-127, 2008
19. Nielsen S, Lihn AS, Ostergaard T, Mogensen CE, Schmitz O: Increased plasma adiponectin in losartan-treated type 1 diabetic patients: a mediator of improved insulin sensitivity. Horm Metab Res 36:194 -196, 2004
20. Maahs DM, Ogden LG, Snell-Bergeon JK, Kinney GL, Wadwa RP, Hokanson JE, Dabelea D, Kretowski A, Eckel RH, Rewers M: Determinants of serum adiponectin in persons with and without type 1 diabetes. Am J Epidemiol 166:731-740, 2007
21. Wang Y, Xu A, Knight C, Xu LY, Cooper GJS: Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. J Biol Chem 277:19521-19529, 2002
22. Wang Y, Lam KS, Chan L, Chan KW, Lam JBB, Lam MC, Hoo RCL, Mak WMK, Cooper GJS, Xu A: Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J Biol Chem 16391-16400, 2006
23. Richards AA, Stephens T, Charlton HK, Jones A, Macdonald GA, Prins JB, White-head JP: Adiponectin multimerization is dependent on conserved lysines in the collagenous domain: evidence for regulation of multimerization by alterations in posttranslational modifications. Mol Endocrinol 20:1673-1687, 2006